Serum trace metals in chronic viral hepatitis and hepatocellular carcinoma in Thailand

1994 ◽  
Vol 29 (5) ◽  
pp. 610-615 ◽  
Author(s):  
C. Pramoolsinsap ◽  
N. Promvanit ◽  
S. Komindr ◽  
P. Lerdverasirikul ◽  
S. Srianujata
Keyword(s):  
Hepatocellular Carcinoma ◽  
Trace Metals ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

scholarly journals The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma

2021 ◽  
Author(s):  
Cortlandt M. Sellers ◽  
Johannes Uhlig ◽  
Johannes M. Ludwig ◽  
Jeffrey S. Pollak ◽  
Tamar H. Taddei ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Prognostic Value ◽  
Chronic Viral Hepatitis ◽  
Inflammatory Biomarkers

Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma

2009 ◽  
Vol 150 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Alajos Pár
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Mivel a hepatitis B- és C-vírus- (HBV-, HCV-) fertőzés döntő szerepet játszik a hepatocellularis carcinoma (HCC) keletkezésében, a HBV és HCV okozta hepatitis és cirrhosis megelőzése és kezelése egyben a HCC prevencióját is jelentheti. A HCC primer prevencióját képviseli a HBV elleni vakcináció és a donorok szűrése HBV- és HCV-markerekre. A szekunder prevencióhoz sorolható az interferonalapú és/vagy nukleozidanalóg anti-HBV- és anti-HCV-terápia, a cirrhosisos betegek HCC irányában történő alfa-foetoprotein + ultrahang szűrése, valamint a HCC kuratív reszekciója/ablatiója utáni adjuváns antivirális kezelés. Várható, hogy a HBV-vakcináció világszerte történő széles körű alkalmazása, továbbá az optimalizált individuális antivirális kezelésmódok, az új nukleozidanalógok és HCV-specifikus proteáz- és polimerázgátlók révén előrelépés történik nemcsak a vírushepatitisek megelőzésében és terápiájában, hanem a HCC prevenciójában is a nem túl távoli jövőben.

Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma

2003 ◽  
Vol 3 (8) ◽  
pp. 1169-1176 ◽  
Author(s):  
G Rasi ◽  
P Pierimarchi ◽  
P Sinibaldi Vallebona ◽  
F Colella ◽  
E Garaci
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma

2000 ◽  
Vol 99 (3) ◽  
pp. 207-214 ◽  
Author(s):  
Michiko OKUBO ◽  
Goshi SHIOTA ◽  
Hironaka KAWASAKI
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Liver Diseases ◽  
Total Mass ◽  
Sandwich Elisa ◽  
Chronic Viral Hepatitis ◽  
Rt Pcr ◽  
Platelet Counts ◽  
Indocyanine Green Test ◽  
Normal Controls

Thrombocytopenia in liver diseases is considered to be due to splenic platelet pooling and accelerated destruction. Since thrombopoietin (TPO), a regulator of thrombopoiesis, is produced mainly in the liver, decreased production of TPO may account for thrombocytopenia in liver diseases. To address this issue, we measured serum TPO, using a sensitive sandwich ELISA, in 108 patients with chronic viral hepatitis, which included chronic hepatitis (CH) and liver cirrhosis (LC), and hepatocellular carcinoma (HCC), and in 29 normal controls. TPO mRNA in 78 liver samples was examined by reverse transcription (RT)-PCR. Platelet counts in CH, LC, HCC and controls were 176±15×109/l, 81±8×109/l, 99±7×109/l and 234±9×109/l respectively. Serum TPO levels in CH, LC and HCC were 2.79±0.4 fmol/ml, 1.49±0.2 fmol/ml and 1.97±0.2 fmol/ml, and were higher than those of controls. Serum TPO levels were positively correlated with prothrombin time and serum albumin (P < 0.05, in each case), and negatively correlated with Indocyanine Green test and Pugh score (P < 0.01 and P < 0.05 respectively). However, RT-PCR and immunohistochemistry showed that expression of TPO mRNA and protein were similar in the different liver diseases, suggesting that serum TPO is a reflection of the total mass of functional liver. Platelet counts were negatively correlated with spleen index, but not with serum TPO. These results suggest that thrombocytopenia in liver disease is not directly associated with serum TPO but is associated with hypersplenism.

scholarly journals Hepatocellular carcinoma (HCC); aetiological considerations

2015 ◽  
Vol 1 (1) ◽  
pp. 18 ◽  
Author(s):  
Omar Abdel-Rahman
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Hepatocellular carcinoma (HCC) is a commonly occurring cancer worldwide. The aetiology of HCC, often associated with different molecular carcinogenic pathways, differs geographically; with chronic viral hepatitis being the main cause in most localities. Different driving mutations resulting from distinct carcinogenic pathways potentially impact the choice of effective therapies for HCC.

scholarly journals Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

2022 ◽  
Vol 23 (1) ◽  
pp. 500
Author(s):  
Francesco Paolo Russo ◽  
Alberto Zanetto ◽  
Elisa Pinto ◽  
Sara Battistella ◽  
Barbara Penzo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Virological Suppression ◽  
Risk Patients ◽  
Related Liver Disease ◽  
Direct Acting ◽  
Cell Signaling Pathways

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death. Although the burden of alcohol- and NASH-related HCC is growing, chronic viral hepatitis (HBV and HCV) remains a major cause of HCC development worldwide. The pathophysiology of viral-related HCC includes liver inflammation, oxidative stress, and deregulation of cell signaling pathways. HBV is particularly oncogenic because, contrary to HCV, integrates in the cell DNA and persists despite virological suppression by nucleotide analogues. Surveillance by six-month ultrasound is recommended in patients with cirrhosis and in “high-risk” patients with chronic HBV infection. Antiviral therapy reduces the risks of development and recurrence of HCC; however, patients with advanced chronic liver disease remain at risk of HCC despite virological suppression/cure and should therefore continue surveillance. Multiple scores have been developed in patients with chronic hepatitis B to predict the risk of HCC development and may be used to stratify individual patient’s risk. In patients with HCV-related liver disease who achieve sustained virological response by direct acting antivirals, there is a strong need for markers/scores to predict long-term risk of HCC. In this review, we discuss the most recent advances regarding viral-related HCC.

scholarly journals Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis

Cancer ◽  
2006 ◽  
Vol 106 (3) ◽  
pp. 636-647 ◽  
Author(s):  
Masahiro Kobayashi ◽  
Kenji Ikeda ◽  
Tetsuya Hosaka ◽  
Hitomi Sezaki ◽  
Takashi Someya ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Dysplastic Nodules

Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma

2008 ◽  
Vol 9 (13) ◽  
pp. 2233-2245
Author(s):  
Mark A Feitelson ◽  
Marcia M Clayton ◽  
Helena MGPV Reis ◽  
Guoyi Wu ◽  
Eva Ping Lu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis
Sign in / Sign up

Export Citation Format

Share Document